Insights

Acquisition by Bristol Myers Squibb Mirati Therapeutics' acquisition by Bristol Myers Squibb presents an opportunity for cross-selling products and services to a wider customer base, leveraging the resources and networks of a larger organization.

Financially Healthy With reported revenue between $50M - $100M and substantial funding of $345M, Mirati Therapeutics demonstrates financial stability and potential for significant sales opportunities, indicating capacity for sizable purchases or collaborations.

Competitive Landscape Mirati Therapeutics' similarity with companies like Blueprint Medicines, Deciphera Pharmaceuticals, and Revolution Medicines, with comparable employee size and revenue, hints at a market segment where solutions from these companies may complement each other and lead to strategic partnerships or acquisitions.

Biotechnology Research Focus Being in the biotechnology research industry, Mirati Therapeutics aligns with the current industry trends focused on developing cutting-edge therapies. This industry trend offers potential collaborations, licensing agreements, or joint ventures with other biotech companies aiming to revolutionize cancer treatments.

Technology Utilization Mirati Therapeutics employs various technologies like Google Analytics, Oracle Business Intelligence, and SAP ABAP. Leveraging these tech solutions could provide opportunities for tech integrations or partnerships with other companies in the industry seeking to enhance data analytics or operational efficiencies.

Mirati Therapeutics Tech Stack

Mirati Therapeutics uses 8 technology products and services including Google Analytics, Oracle Business Intelligence, OpenStack, and more. Explore Mirati Therapeutics's tech stack below.

  • Google Analytics
    Analytics
  • Oracle Business Intelligence
    Business Intelligence
  • OpenStack
    Infrastructure As A Service
  • BT
    IT Infrastructure
  • SAP ABAP
    Programming Languages
  • Base SAS
    Software As A Service
  • DHL
    Transportation And Fleet Management
  • Linkedin
    Widgets

Media & News

Mirati Therapeutics's Email Address Formats

Mirati Therapeutics uses at least 2 format(s):
Mirati Therapeutics Email FormatsExamplePercentage
LastF@mirati.comDoeJ@mirati.com
88%
FLast@mirati.comJDoe@mirati.com
5%
Last@mirati.comDoe@mirati.com
4%
First@mirati.comJohn@mirati.com
1%
FirstL@mirati.comJohnD@mirati.com
1%
LF@mirati.comDJ@mirati.com
1%
First.Last@bms.comJohn.Doe@bms.com
94%
LastF@bms.comDoeJ@bms.com
3%
Last.First@bms.comDoe.John@bms.com
2%
First.Middle@bms.comJohn.Michael@bms.com
1%

Frequently Asked Questions

Where is Mirati Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Mirati Therapeutics's main headquarters is located at 3545 Cray Ct San Diego, California 92121 US. The company has employees across 4 continents, including North AmericaEuropeAfrica.

What is Mirati Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Mirati Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Mirati Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Mirati Therapeutics is a publicly traded company; the company's stock symbol is MRTX.

What is Mirati Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Mirati Therapeutics's official website is bms.com and has social profiles on LinkedIn.

How much revenue does Mirati Therapeutics generate?

Minus sign iconPlus sign icon
As of September 2024, Mirati Therapeutics's annual revenue reached $75M.

What is Mirati Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Mirati Therapeutics's SIC code is 2834 - Pharmaceutical Preparations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Mirati Therapeutics have currently?

Minus sign iconPlus sign icon
As of September 2024, Mirati Therapeutics has approximately 201 employees across 4 continents, including North AmericaEuropeAfrica. Key team members include Chief Executive Officer: D. M.Chief Commercial Officer: B. H.Chief Financial Officer: A. O.. Explore Mirati Therapeutics's employee directory with LeadIQ.

What industry does Mirati Therapeutics belong to?

Minus sign iconPlus sign icon
Mirati Therapeutics operates in the Biotechnology Research industry.

What technology does Mirati Therapeutics use?

Minus sign iconPlus sign icon
Mirati Therapeutics's tech stack includes Google AnalyticsOracle Business IntelligenceOpenStackBTSAP ABAPBase SASDHLLinkedin.

What is Mirati Therapeutics's email format?

Minus sign iconPlus sign icon
Mirati Therapeutics's email format typically follows the pattern of . Find more Mirati Therapeutics email formats with LeadIQ.

How much funding has Mirati Therapeutics raised to date?

Minus sign iconPlus sign icon
As of September 2024, Mirati Therapeutics has raised $345M in funding. The last funding round occurred on Aug 09, 2023 for $345M.

When was Mirati Therapeutics founded?

Minus sign iconPlus sign icon
Mirati Therapeutics was founded in 2013.
Mirati Therapeutics

Mirati Therapeutics

Biotechnology ResearchCalifornia, United States201-500 Employees

Mirati Therapeutics, Inc. is now part of Bristol Myers Squibb. Follow our progress delivering breakthrough therapies that target the genetic drivers of cancer @Bristol Myers Squibb or www.bms.com

Section iconCompany Overview

Headquarters
3545 Cray Ct San Diego, California 92121 US
Phone number
Website
bms.com
SIC Code
2834 - Pharmaceutical Preparations
Stock Symbol
MRTX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
201-500

Section iconMedia & News

Section iconFunding & Financials

  • $345M

    Mirati Therapeutics has raised a total of $345M of funding over 8 rounds. Their latest funding round was raised on Aug 09, 2023 in the amount of $345M.

  • $50M$100M

    Mirati Therapeutics's revenue is in the range of $50M$100M

Section iconFunding & Financials

  • $345M

    Mirati Therapeutics has raised a total of $345M of funding over 8 rounds. Their latest funding round was raised on Aug 09, 2023 in the amount of $345M.

  • $50M$100M

    Mirati Therapeutics's revenue is in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.